Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Ahoua, Laurence ^a   Guenther, Gunar ^a   Pinoges, Loretxu ^a   Anguzu, Paul ^b   Chaix, Marie Laure ^c   Le Tiec, Clotilde ^d   Balkan, Suna ^b   Olson, David ^b   Olaro, Charles ^e   Pujades Rodríguez, Mar ^a,f  

^a HIV/AIDS Department   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICÊTRE HOSPITAL   (France)

^e Medical and Administrative Hospital Direction   (Uganda)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ADHERENCE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COMPLIANCE; RISK FACTOR; RURAL AREA; SUBTHERAPEUTIC ANTIRETROVIRAL THERAPY; TUBERCULOSIS; UGANDA; VIROLOGY; VIRUS IMMUNITY; ANTIVIRAL RESISTANCE; BLOOD; DEVELOPING COUNTRY; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; RETROSPECTIVE STUDY; RURAL POPULATION; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; LOGISTIC MODELS; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; RURAL POPULATION; TREATMENT OUTCOME; UGANDA;

EID: 67649848130     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-81     Document Type: Article

References (47)

1. UNAIDS Epidemiological fact sheets on HIV/AIDS and STIs. Uganda; 2008 update http://www.unaids.org/en/Regions_Countries/Countries/Uganda.asp
2. Kebba A Atwine D Mwebaze R Kityo C Nakityo R Peter M Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients AIDS Res Hum Retroviruses 2002, 18:1181-1187. 10.1089/08892220260387922 12487824
3. Weidle PJ Malamba S Mwebaze R et al Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance Lancet 2002, 360:34-40. 10.1016/S0140-6736(02)09330-3 12114039
4. DART Virology Group and Trial Team Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa AIDS 2006, 20:1391-1399. 16791013
5. Kabugo C Bahendeka S Mwebaze R et al Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: Evidence of extended virologic and CD4+ cell count responses J Acquir Immune Defic Syndr 2005, 38:578-583. 10.1097/01.qai.0000134742.26338.2f 15793369
6. Spacek LA Shihab HM Kamya MR et al Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda Clin Infect Dis 2006, 42:252-259. 10.1086/499044 16355337
7. Kamya MR Mayanja-Kizza H Kambugu A et al Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy J Acquir Immune Defic Syndr 2007, 46:187-193. 10.1097/ QAI.0b013e31814278c0 17693883
8. Gilks CF Crowley S Ekpini R et alThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings Lancet 2006, 368:505-510. 10.1016/S0140-6736(06)69158-7 16890837
9. World Health Organization Scaling up access to antiretroviral therapy in Resource-limited settings: Treatment guidelines for a public health approach. 2003 revision Geneva: WHO 2004
10. Ferradini L Jeannin A Pinoges L et al Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment Lancet 2006, 367:1335-1342. 10.1016/S0140-6736(06)68580-2 16631912
11. Coetzee D Hildebrand K Boulle A et al Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa AIDS 2004, 18:887-895. 10.1097/00002030-200404090-00006 15060436
12. Wu EY Wilkinson JM Naret DG et al High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma J Chromatogr B Biomed Sci Appl 1997, 695:373-380. 10.1016/S0378-4347(97)00193-X 9300874
13. van Heeswijk RP Hoetelmans RM Meenhorst PL Mulder JW Beijnen JH Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection J Chromatogr B Biomed Sci Appl 1998, 713:395-399. 10.1016/ S0378-4347(98)00217-5 9746255
14. Rouet F Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting J Clin Microbiol 2005, 43:2709-2717. 1151915 15956387 10.1128/JCM.43.6.2709-2717.2005
15. Descamps D French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-202 J Acquir Immune Defic Syndr 2005, 38:545-552. 10.1097/ 01.qai.0000155201.51232.2e 15793364
16. ANRS The French ANRS (National Agency for AIDS Research) AC11 HIV-1 Resistance Group: HIV-1 genotypic drug resistance interpretation algorithms http://www.hivfrenchresistance.org
17. AIDS Clinical Trial Group Division of AIDS table for grading the severity of adult and pediatric adverse events 2004 http://www.aactg.org/
18. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach Geneva: WHO 2006
19. World Health Organization WHO consultation on ART failure in the context of public health approach. Draft meeting report Geneva: WHO 2008
20. Taburet AM Garrafo R Goujard C Molina M Peytavin G Treluyer JM [Pharmacologie des Antirétroviraux: Indications des dosages plasmatiques des antirétroviraux] Prise en charge médicale des personnes infectées par le VIH. Rapport 2006, Recommandations du groupe d'experts Sous la direction du Professeur Patrick Yeni Paris: République Française. Ministère de la Santé et des solidarités Flammarion SA, Direction Générale de la Sante ANRS 2006 171 184
21. Bouyer J Hémon D Cordier S et al Epidemiologie, principes et méthodes quantitatives INSERM ed. Paris 1995
22. Djomand G Roels T Ellerbrock T et al Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire AIDS 2003, 17(Suppl 3):S5-S15. 14565604
23. Libamba E Makombe S Mhango E et al Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi Bull World Health Organ 2006, 84:320-326. 2627329 16628306
24. Stringer JS Zulu I Levy J et al Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes JAMA 2006, 296:782-793. 10.1001/jama.296.7.782 16905784
25. Braitstein P Brinkhof MW Dabis F et al Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries Lancet 2006, 367:817-824. 10.1016/ S0140-6736(06)68337-2 16530575
26. Etard JF Ndiaye I Thierry-Mieg M et al Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: A 7-year cohort study AIDS 2006, 20:1181-1189. 10.1097/ 01.aids.0000226959.87471.01 16691070
27. Zachariah R Fitzgerald M Massaquoi M et al Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi AIDS 2006, 20:2355-2360. 10.1097/QAD.0b013e32801086b0 17117022
28. Anabwani G Navario P Nutrition and HIV/AIDS in sub-Saharan Africa: An overview Nutrition 2005, 21:96-99. 10.1016/j.nut.2004.09.013 15661483
29. Badri M Lawn SD Wood R Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: A longitudinal study Lancet 2006, 368:1254-1259. 10.1016/ S0140-6736(06)69117-4 17027731
30. DeSimone JA Pomerantz RJ Babinchak TJ et al Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Ann Intern Med 2000, 133:447-454. 10975963
31. Gandhi NR Moll A Sturm AW Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa Lancet 2006, 368:1575-1580. 10.1016/ S0140-6736(06)69573-1 17084757
32. Weidle PJ Wamai N Solberg P et al Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda Lancet 2006, 368:1587-1594. 10.1016/S0140-6736(06)69118-6 17084759
33. Diamond C Richardson JL Milam J et al Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients J Acquir Immune Defic Syndr 2005M 39:211-218. 15905739
34. Russell J Krantz S Neville S The patient-provider relationship and adherence to highly active antiretroviral therapy J Assoc Nurses AIDS Care 2004, 15:40-47. 10.1177/1055329004269283 15358924
35. Laurent C Ngom Gueye NF Ndour CT et al Long-term benefits of highly active antiretroviral therapy in senegalese HIV-1-infected adults J Acquir Immune Defic Syndr 2005, 38:14-17. 10.1097/ 00126334-200501010-00003 15608518
36. Sow PS Otieno LF Bissagnene E et al Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: Clinical results from 4 African countries J Acquir Immune Defic Syndr 2007, 44:262-267. 10.1097/QAI.0b013e31802bf109 17146376
37. Bartlett JA DeMasi R Quinn J Moxham C Rousseau F Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults AIDS 2001, 15:1369-1377. 10.1097/ 00002030-200107270-00006 11504958
38. Ferradini L Laureillard D Prak N et al Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia AIDS 2007, 21:2293-2301. 10.1097/QAD.0b013e32828cc8b7 18090277
39. Cohen K Van CG Boulle A et al Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis J Antimicrob Chemother 2008, 61:389-393. 10.1093/jac/dkm484 18096560
40. Autar RS Wit FW Sankote J et al Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis Antivir Ther 2005, 10:937-943. 16430199
41. Ribera E Pou L Lopez RM et al Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis J Acquir Immune Defic Syndr 2001, 28:450-453. 11744833
42. Dean GL Back DJ de RA Effect of tuberculosis therapy on nevirapine trough plasma concentrations AIDS 1999, 13:2489-2490. 10.1097/ 00002030-199912030-00029 10597799
43. Boulle A Van CG Cohen K et al Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy JAMA 2008, 300:530-539. 10.1001/ jama.300.5.530 18677025
44. van Oosterhout JJ Bodasing N Kumwenda JJ et al Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi Trop Med Int Health 2005, 10:464-470. 10.1111/ j.1365-3156.2005.01409.x 15860093
45. Donnerer J Kronawetter M Kapper A Haas I Kessler HH Therapeutic drug monitoring of the HIV/AIDS drugs abacavir,. zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir Pharmacology 2003, 69:197-204. 10.1159/000073664 14624060
46. Zhou XJ Sheiner LB D'Aquila RT et al Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 1999, 43:121-128. 89031 9869576
47. Mills EJ Nachega JB Buchan I et al Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis JAMA 2006, 296:679-690. 10.1001/jama.296.6.679 16896111